Due to recent findings of the MDM2 SNP309T>G polymorphism enhancing MDM2 transcription and its potential association to increased cancer risk [9], we hypothesized that the MDM2 SNP309G genotype may be associated with lack of response to an anthracycline regimen. The gene discussed is MDM2; the disease is cancer.